Imogam Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high rabies mortality rates, limited early access to vaccines, reliance on passive immunity products, public health vaccination programs, hospital based emergency care.

The growth in the forecast period can be attributed to increasing animal bite incidents, expansion of rabies awareness campaigns, growth in emergency healthcare infrastructure, improved access to immunoglobulins, rising government investment in zoonotic control. Major trends in the forecast period include continued demand for rabies post exposure prophylaxis, expansion of passive immunization use, rising focus on zoonotic disease prevention, growth in emergency immunoglobulin administration, strengthening public health preparedness.

The increasing incidence of animal bites is expected to drive the growth of the Imogam market moving forward. Animal bites refer to incidents where individuals are bitten by animals, leading to injuries that may require medical attention. The rise in animal bite incidents is due to factors such as a growing pet population, inadequate animal control, and increased human-animal interactions. Imogam is used for immediate post-exposure prophylaxis in animal bite victims to provide passive immunity against rabies until the rabies vaccine takes effect. For example, in September 2024, an article published by Dogster, a US-based bimonthly magazine and website, reported that in 2023, there were 6,000 dog bite incidents. Furthermore, fatalities from dog bites increased fivefold, from 5 in 2022 to 15 in 2023. As a result, the growing incidence of animal bites is contributing to the expansion of the Imogam market.

The rising international travel is expected to drive the growth of the Imogam market moving forward. Increased international travel reflects greater global mobility and tourism, driven by factors such as eased restrictions, improved connectivity, and rising disposable incomes. This increase in travel heightens exposure to regions endemic to rabies, thereby boosting the demand for Imogam as a critical post-exposure prophylaxis. For example, in May 2024, the Office for National Statistics, a UK-based national statistical institute and the largest independent producer of official statistics, reported that the number of overseas visitors to the UK rose from 31.2 million in 2022 to 38 million in 2023. As a result, the growing occurrence of animal bites due to increased travel is further fueling the growth of the Imogam market.

The expansion of healthcare infrastructure is also expected to propel the growth of the Imogam market. Healthcare infrastructure encompasses the physical and organizational structures, facilities, resources, and systems needed to deliver healthcare services to a population. The aging global population, the rise in chronic diseases, and technological advancements are all driving the expansion of healthcare infrastructure. A robust healthcare infrastructure is essential for the progress of Imogam, ensuring cold chain maintenance, timely administration, and accessibility in rabies post-exposure prophylaxis. For instance, in May 2024, a report by the Office for National Statistics, a UK-based government agency, showed that total healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of just 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the expansion of healthcare infrastructure is further driving the growth of the Imogam market.

Major companies operating in the imogam market are Sanofi SA.

North America was the largest region in the imogam market in 2025. The regions covered in the imogam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the imogam market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the imogam market by increasing costs associated with plasma collection, immunoglobulin purification, and cold chain transportation. These impacts are most significant for hospital and emergency care distribution channels, particularly in regions dependent on imported human rabies immune globulin. Higher tariffs can strain public health budgets and delay availability in high risk areas. Conversely, tariffs are encouraging regional plasma fractionation, domestic immunoglobulin production, and stronger self sufficiency in critical rabies prevention supplies.

The imogam market research report is one of a series of new reports that provides imogam market statistics, including imogam industry global market size, regional shares, competitors with a imogam market share, detailed imogam market segments, market trends and opportunities, and any further data you may need to thrive in the imogam industry. This imogam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Imogam is a brand name for a human rabies immune globulin (HRIG) product used as part of post-exposure prophylaxis (PEP) to prevent rabies infection after exposure to the rabies virus. The product provides passive immunity by supplying antibodies against rabies.

The primary patient demographics for Imogam include pediatric patients, adult patients, and high-risk groups. Pediatric patients refer to children who are at risk of contracting rabies due to animal bites or scratches. Treatment for pediatric patients often involves age-specific dosages of rabies vaccines and rabies immune globulin, such as Imogam, to prevent infection. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and pharmacies, and is used for applications like post-exposure prophylaxis and pre-exposure prophylaxis.

The imogam market consists of sales of imogam rabies-HT 150 IU/mL vial, and imogam injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.